OS Therapies announced that the European Medicines Agency (EMA) has started a rolling review of its OST-HER2 immunotherapy for osteosarcoma, targeting early market access via Conditional Marketing Authorizations in Europe, the UK, and Australia. The company achieved regulatory alignment on key clinical endpoints and plans to initiate a confirmatory Phase 3 trial in Q3 2026. OST-HER2 received Advanced Therapy Medicinal Product designation in the UK and is forecasted to generate over $300 million in peak European sales, with $50 million expected in 2027. Upcoming milestones include FDA and MHRA meetings and submission of Biologics License Applications under accelerated approval pathways.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Bitcoin price recently hit a strong resistance level at $65,600 but failed to break through, signaling a possible reversal. Short-term momentum is weakening, suggesting the price may decline unless a sudden surge occurs. Key support levels include th...
